Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression, Unipolar, Depression, Bipola...
Phase NA
Enrollment 231
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Bright Light Therapy (BLT) is a proven treatment for depression in seasonal and non-seasonal depressive disorders, as well as bipolar disorder. To make BLT more effective and practical in clinical settings and tailor it to individual needs, it is necessary to optimize the treatment approach, understand how the treatment works, and identify patient characteristics that predict response. This clinical trial has three main goals: * Optimize the administration of BLT for patients with depressive episodes. * Gain a deeper understanding of the treatment mechanisms. * Determine which patients benefit the most from the treatment. The specific objectives are as follows: * Investigate whether additional treatments and interventions related to lifestyle and the biological clock can enhance the effects of BLT. * Examine how BLT influences the body's internal clock and sleep quality, and how these factors contribute to the outcomes. * Identify patient characteristics and behaviours that can predict treatment outcomes. * Develop a brain model to better understand the impact of BLT on the brain. In this study, patients will receive BLT with a light intensity of 10,000 lux for 30 minutes each morning over 5 consecutive days. The treatment duration will range from one to three weeks, depending on the improvement of depressive symptoms. Participants will be randomly assigned to one of three groups: * Home - Patients will receive BLT at home, following the standard guidelines for light therapy in the Netherlands. * LightCafé, fixed time: Patients will receive BLT in a café-like setting called the LightCafé, where the focus is not only on symptom improvement but also lifestyle enhancements and fostering social connections. The treatment time will be the same every day. * LightCafé, varying time: Patients will also receive BLT at the LightCafé, with treatment timing varying each day. Additionally, this group will wear glasses in the evening that filter blue light. The study includes a baseline phase of up to two weeks, a treatment phase of up to three weeks, and a three-month follow-up phase. Patients will wear a motion watch to assess sleep-wake behaviour and physical activity during the day. Additionally, they will wear a broach that measures their personal light exposure throughout the day. Eight one-minute questionnaires per day will be sent to the participants' smartphones to assess vitality, sleep, and mood during the treatment. Predictors of treatment response, such as clinical characteristics, sleep measures, circadian parameters, and light-related behaviours, will be evaluated at baseline. In a small group of patients, salivary melatonin curves will be assessed before and after treatment. MRI scans will provide insights into functional and structural brain changes following light therapy treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: Bright Light Therapy — In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
  • Device: Blue Light Blocking Glasses — Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.

Primary Outcomes

  • Clinical Improvement (2-5 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-08
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 231 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universiteit Leiden
Collaborators: Eindhoven University of Technology, Geestelijke Gezondheidszorg Eindhoven (GGzE), Chrono@Work B.V.
Principal Investigators:
  • Niki Antypa, PhD (PRINCIPAL_INVESTIGATOR) - Leiden University
Contact Information
Study Contact:
Niki Antypa, PhD
+31 71 527 6677
nantypa@fsw.leidenuniv.nl
Luc Schlangen, PhD
Emma Visser, MSc
+31622143145
e.visser1@tue.nl
GGzE - Mental Health Institute of Eindhoven and the Kempen
Interventions
  • Procedure: Bright Light Therapy — In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
  • Device: Blue Light Blocking Glasses — Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
Study Locations (2 sites)
GGzE - Mental Health Institute of Eindhoven and the Kempen, Eindhoven, 5626 ND Netherlands
Leids Universitair Behandel- en Expertise Centrum, Leiden, 5626 ND Netherlands
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 65. * Diagnosis of unipolar or bipolar depression (seasonal or non-seasonal) as assessed with the Mini-International Neuropsychiatric Interview (M.I.N.I.) * A current depressive episode (a score of 6 or higher on the Quick Inventory of depressive symptomatology Self Report (QIDS-SR) * Sufficient knowledge of Dutch or English language to fill in questionnaires * Provided Informed consent Exclusion Criteria: * A current (hypo)manic or mixed episode (as assessed with the M.I.N.I.) * Current psychotic episode (as assessed with the M.I.N.I.) * Prominent active suicidality (score 10 or higher on the M.I.N.I. module) * Antidepressant therapy (medication, psychotherapy or BLT, or other forms of specific treatments for depression) that started less than 2 months prior to study entry * participants with bipolar disorder should be in mood-stabilizing treatment for at least 1 month in a recommended dosage, * Use of melatonin or agomelatine in the last month * Current use of antibiotics * Current use of light sensitivity increasing medication * Travelled across more than 1 time zone during past month or during the treatment * Travelled to sunny holiday locations/winter sports during past month * pre-existing eye and skin disorders (retinitis pigmentosa, porphyria, chronic actinic dermatitis and sun-induced urticaria) * Systemic disorders with potential retinal involvement (rheumatoid arthritis and systemic lupus erythematosus) * Suffering from colour blindness (assessed by Ishihara colour plates) * Participated in night shift work in the last three months * (Retinal) blindness, severe cataract and glaucoma * Light-induced migraine or epilepsy * Pregnancy, or parents with a child younger than 18 months old
Conditions Glaucoma
Phase NA
Enrollment 144
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is a complex disease that can result in progressive vision loss. It is the second leading cause of blindness, accounting for 23% of permanent blindness in Hong Kong. There are no treatments that restore vision lost to glaucoma. However, recent studies have shown that vision can be improved by perceptual learning (PL) and transcranial electrical stimulation (tES). This study will examine the effect of perceptual learning and tES on improving quality of life, visual function and functional performance in patients with peripheral field loss due to glaucoma. It is phase 2 of Glaucoma Rehabilitation Using ElectricAI Transcranial Stimulation (GREAT) project.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Other: Real-PL training + Real-tES(tDCS) — PLtraining : around 40mins, tDCS: 20mins
  • Other: Real-PL training + Sham-tES (tDCS) — PL training : around 40mins, tDCS: 20mins
  • Other: Placebo-PL training + Sham-tES (tDCS) — PL training : around 40mins, tDCS: 20mins

Primary Outcomes

  • Visual field test (Change from baseline at 5weeks, change from baseline at 10weeks, change from baseline at 15weeks, change from baseline at 19weeks, changes from baseline at 23weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-15
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 144 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hong Kong Polytechnic University
Collaborators: The University of Hong Kong, University of Waterloo, University of Magdeburg
Contact Information
Study Contact:
Allen Cheong, PhD
852-27666108
allen.my.cheong@polyu.edu.hk
Melinna Mei, PhD
852-34002309
melinna.mei@polyu.edu.hk
Allen Cheong, PhD
852-27666108
allen.my.cheong@polyu.edu.hk
The Hong Kong Polytechnic University
Interventions
  • Other: Real-PL training + Real-tES(tDCS) — PLtraining : around 40mins, tDCS: 20mins
  • Other: Real-PL training + Sham-tES (tDCS) — PL training : around 40mins, tDCS: 20mins
  • Other: Placebo-PL training + Sham-tES (tDCS) — PL training : around 40mins, tDCS: 20mins
Study Locations (1 sites)
The Hong Kong Polytechnic University, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Age range from 18 to 80 years; * Diagnosis of primary open angle or normal tension glaucoma with relative scotoma in both eyes; * A relative scotoma defined as a Humphrey Field Analyser (HFA) threshold perimetry loss (mean deviation of -6dB) within the central 24 degree of the visual field for at least one eye; * Best-corrected distance visual acuity of 6/12 or better (equivalent to 0.3 logMAR acuity or better to confirm that participant's central vision is preserved). * Stable vision and visual field loss for at least 3 months; * With a cognitive functional score of 22 or above in the Montreal Cognitive Assessment - Hong Kong version (HK-MoCA) (to confirm participant's intact cognitive function). Exclusion Criteria: * Ocular diseases other than glaucoma (e.g. age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participant can hear the instructions clearly during assessments and training); * Severe medical problems (e.g. stroke, Parkinson's disease) or self-reported neurological (e.g. brain surgery, brain tumor, peripheral neuropathy), or cognitive disorders (e.g. diagnosed dementia or cognitive impairment); * Self-reported vestibular or cerebellar dysfunction, history of vertigo; * Using any medications for any neurological conditions or psychiatric drugs (e.g. sedative, hypnotic) that might interfere motor control; * Contraindications for non-invasive brain stimulation.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 190
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate clinical outcomes and adverse events of salvage treatment for locoregional recurrence of breast cancer. The main questions it aims to answer are: * Clinical outcomes after salvage treatment for locoregional recurrence * Adverse events and quality of life after salvage treatment for locoregional recurrence * Patient characteristics and treatment specifics which are related to the clinical outcomes and/or adverse events * Molecular signature associated with treatment resistance Participants will be assessed by multi-dimensional methods during and after radiation therapy: * Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * Assessment for the adverse events according to CTCAE version 5.0 * Assessment for the molecular signature using residual tissue after pathologic diagnosis * Assessment for the quality of life using questionnaires (BREAST-Q)

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Salvage treatment (surgery and/or radiation therapy) — Appropriate salvage treatment (surgery and/or radiation therapy) will be selected by the treating clinicians considering the disease status.

Primary Outcomes

  • Progression-free survival (5 years from the initiation of the salvage therapy)
  • Rate of adverse events (5 years from the initiation of the salvage therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-04
Completion: 2033-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 190 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Samsung Medical Center
Principal Investigators:
  • Haeyoung Kim (PRINCIPAL_INVESTIGATOR) - Samsung Medical Center
Contact Information
Study Contact:
Haeyoung Kim, MD, PhD
82-2-3410-2612
haeyoung0131.kim@samsung.com
Haeyoung Kim, MD, PhD
82-2-3410-2612
haeyoung0131.kim@samsung.com
Samsung Medical Center
Interventions
  • Other: Salvage treatment (surgery and/or radiation therapy) — Appropriate salvage treatment (surgery and/or radiation therapy) will be selected by the treating clinicians considering the disease status.
Study Locations (1 sites)
Samsung Medical Center, Seoul, 06351 South Korea
Eligibility Criteria
Inclusion Criteria: * Female patients with age 18 to 100. * Previous standard definitive treatment for initial breast cancer * Locoregional recurrence without distant metastasis * Planned salvage treatment for locoregional recurrence * Informed consent of the participant Exclusion Criteria: \- Not anticipated for complying the study protocol
Conditions Hypertension, Systolic, Metabolic Syndro...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Device: Air cleaners with HEPA filter — PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
  • Device: Air cleaners without HEPA filter — Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.

Primary Outcomes

  • Change in Systolic Blood Pressure (week 4, week 10)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-03
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Cornell Medical College in Qatar
Collaborators: Hamad Medical Corporation, Case Western Reserve University
Principal Investigators:
  • Charbel Abi Khalil, MD (PRINCIPAL_INVESTIGATOR) - Weill Cornell Medical College in Qatar
Contact Information
Study Contact:
Charbel Abi Khalil, MD
+974 4492 8484
cha2022@qatar-med.cornell.edu
Jassim Al-Suwaidi, MD
+974 4439 5354
jalsuwaidi@hamad.qa
Hamad Medical Corporation
Charbel Abi Khalil, MD, PhD
Hamad Medical Corporation
Interventions
  • Device: Air cleaners with HEPA filter — PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
  • Device: Air cleaners without HEPA filter — Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
Study Locations (1 sites)
Hamad Medical Corporation, Doha, Qatar
Eligibility Criteria
Inclusion Criteria: * Non-smokers (100% abstinence from use of any smoking or vaping product during the prior year) * Age ≥18 and less than 60 years old * Living in a single residence (home, apartment) located anywhere in Qatar * Mild systolic hypertension: screening visit systolic BP 130 to 159 mm Hg (off treatment or taking ≤ 2 BP medications that have been stable without changes during prior 4 weeks) plus ≥ 2 more additional criteria for the metabolic syndrome: * Waist circumference ≥102 cm if male and ≥88 cm if female * Fasting triglycerides ≥150 mg/dL (or taking a triglyceride-lowering medication) * HDL-C ≤ 40 mg/dL if male and ≤ 50 mg/dL if female (or taking an HDL-raising medication), * Fasting glucose ≥100 mg/dL Exclusion Criteria: * Pregnancy (self-reported) * Screening visit urine positive for cotinine (NicAlert \>100 ng/mL) * Living with an active smoker who smokes indoors (by self-report) * High risk conditions that prohibit allowing home BP to be \>130/80 mm Hg during the10-week trial including any cardiovascular disease (coronary artery disease, prior stroke, heart failure, peripheral arterial disease, aneurysm) or ≥ stage 3 kidney disease (estimated glomerular filtration rate \< 60 ml/min) * A medical condition placing the participant at risk from participation (per investigators) * Expected overnight travel outside their residence during the study * HEPA filter within the air conditioners of the residence (self-reported) or individual use of HEPA filter * Unable to comprehend/sign an informed consent * Lung disease requiring oxygen * Cancer receiving treatment * Screening visit: BP ≥160/100 mm Hg or fasting blood glucose ≥126 mg/dL and confirmed diabetes with follow-up HbA1c ≥6.5%. If glucose is elevated ≥126 mg/dL but HbA1c\<6.5%, they could still participate. * Medication changes in past 4 weeks. If participants are on medications for high BP or hyperlipidemia, they will need to have had stable therapy during prior 10 weeks with no planned changes during the study * Left upper arm circumference \>17 inches as this will make BP levels inaccurate with the home monitor used * Acute illness or infectious symptoms within the prior 4 weeks.
Conditions Epithelial Tumors, Malignant
Phase PHASE1
Enrollment 48
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: MT-302 (A) — MT-302 is an investigational drug

Primary Outcomes

  • To evaluate the safety and tolerability of MT-302 through incidence of Adverse Events (Up to Week 20)
  • To establish the maximum tolerated dose (MTD) (Up to Week 20)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-08-02
Completion: 2028-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Myeloid Therapeutics
Principal Investigators:
  • Matthew Maurer, MD (STUDY_DIRECTOR) - Myeloid Therapeutics
Contact Information
Study Contact:
Shinam Garg
+61 2 9171 3260
Shinam.garg@novotech-cro.com
Clinical Operations
+1 617 465 1022
mt-302clinical@myeloidtx.com
Rasha Cosman, MD
St Vincent's Public Hospital Sydney
Interventions
  • Drug: MT-302 (A) — MT-302 is an investigational drug
Study Locations (6 sites)
St Vincent's Public Hospital Sydney, Darlinghurst, New South Wales 2010 Australia
Scientia Clinical Research Ltd, Randwick, New South Wales 2031 Australia
Westmead Hospital, Westmead, New South Wales 2145 Australia
Souther Oncology Clinical Research Unit (SOCRU), Bedford Park, South Australia 5042 Australia
Cabrini Health, Malvern, Victoria 3144 Australia
Linear Clinical Research Ltd, Nedlands, Western Australia 6009 Australia
Eligibility Criteria
Inclusion Criteria: 1. Adults age ≥ 18 inclusive at the time the Informed Consent Form (ICF) is signed. 2. Histologically proven, metastatic or advanced epithelial cancer including the following cancer types: 1. Urothelial 2. Cervical 3. Ovarian epithelial 4. Triple-negative breast 5. HR+/HER2- breast 6. Pancreatic ductal adenocarcinoma 7. Gastric adenocarcinoma 8. Esophageal carcinoma 9. Non-small cell lung 10. Colorectal 3. Progressive disease at baseline, refractory or relapsed to standard of care or who have declined standard therapy. 4. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria v 1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1. 6. Life expectancy of \> 12 weeks. 7. Echocardiogram (ECHO) or multiple gated acquisition scan showing an ejection fraction greater than or equal to 50%. 8. Electrocardiogram (ECG) showing no clinically significant abnormality at Screening or showing an average QTc interval \< 450 msec in males and \< 470 msec in females (\< 480 msec for participants with bundle branch block). Either Fridericia's or Bazett's formula may be used to correct the QT interval. 9. Oxygen saturation of greater than or equal to 90% on room air measured by pulse oximetry. 10. Adequate organ function as defined by laboratory values at Screening. 11. Willing and able to provide written informed consent. 12. Willing to perform and comply with all study procedures including undergoing study-related biopsies and attending clinic visits as scheduled. 13. Men must abstain from sperm donation during study treatment or for 4 months following last dose of study treatment. 14. Men and WOCBP must be willing to practice a highly effective method of contraception. Exclusion Criteria: 1. Known active CNS metastasis and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression for at least 4 weeks by repeat imaging), clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of study intervention. 2. Pregnant or nursing women. 3. Must be \> 28 days beyond major surgery, including hepatectomy or joint replacement. 4. Prior allogeneic bone marrow transplantation or solid organ transplant. 5. Spinal cord compression not definitively treated with surgery and/or radiation. 6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. 7. Any acute illness including fever (\> 100.4° F or \> 38° C) within 7 days prior to Day 1 8. Active systemic bacterial, fungal, or viral infection within 7 days prior to Day 1. Participant cannot have tested positive for COVID-19 within 7 days prior to Day 1. 9. Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV). 10. Other primary malignancies, except: 1. Adequately treated basal cell or squamous cell carcinoma 2. In situ carcinoma of the cervix or bladder, treated curatively and without evidence of recurrence for at least 2 years prior to the study, or 3. A primary malignancy which has been completely resected and in complete remission for at least 2 years 11. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. 12. Prior grade \> 3 immune-related AEs such as pneumonitis, colitis, hepatitis, nephritis; prior dermatitis and endocrinopathies are allowed provided corticosteroids are no longer required and endocrine-replacement therapy is stable and discontinued from prior therapy. 13. Active autoimmune disease not related to prior therapy for primary malignancy that has required systemic therapy in the last 1 year. 14. History of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious active arrhythmias or other clinically significant cardiac disease within 12 months of enrollment. 15. Toxicity from previous anti-cancer therapy defined as toxicities (other than alopecia, or laboratory values listed above) not yet resolved to NCI CTCAE v5.0 Grade ≤ 1 or baseline. Participants with chronic Grade 2 toxicities (eg, peripheral neuropathy, laboratory values) may be eligible per the discretion of the Investigator and Medical Monitor. 16. Has received: 1. Radiotherapy within 2 weeks of first administration of MT-302 2. Cytotoxic chemotherapy for treatment of the primary malignancy within 28 days or 5 half-lives, whichever is shorter, of administration of MT-302 3. Immune therapy for primary malignancy (eg, monoclonal antibody therapy, checkpoint inhibitors) within 28 days or 5 half-lives, whichever is shorter of first administration of MT-302 4. Targeted therapies for primary malignancy within 28 days or 5 half-lives, whichever is shorter, of first administration of MT-302 5. Anti-cancer vaccine within 12 weeks of first administration of MT-302 6. COVID-19 mRNA vaccine within 6 weeks of first administration of MT-302 17. Has received a live vaccine ≤ 6 weeks prior to first administration of MT-302 18. Has received packed red blood cells or platelet transfusion within 2 weeks prior to first administration of MT-302 19. History of an allergic reaction to any of the excipients 20. Enrollment in another interventional clinical trial within 28 days or 5 half-lives of the drug, whichever is shorter, of first administration of MT-302 21. Any other condition that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with the study requirements.
Conditions Cardiovascular Diseases, Diabete Type 2,...
Phase NA
Enrollment 105
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Nordic Walking (NW) is a biomechanically correct walking technique that originated in Finland in the 1930s as an off-season training method for cross-country skiers. In the NW, the use of special sticks is combined with "conventional" walking: this involves a greater caloric expenditure, with an energy consumption higher by 20-30% compared to walking without sticks, and also toning of the upper part of the body, in particular triceps, shoulders and back, and the involvement of about 90% of the body's muscles, while maintaining a reduced load on ligaments and joints (Baek \& Ha, 2021). The NW acts simultaneously and effectively on different components of fitness: coordination, endurance, strength, and mobility. It does not require sudden accelerations and is based on a technique that is easy to learn (with the help of an instructor), especially as regards maintaining correct posture. Finally, in addition to the cardiovascular benefits, NW has also been shown to effectively reduce the risk of falls in the elderly. The study is a single-center, randomized controlled trial (RCT), with a three-parallel-arm design, open-label. The primary objective is to evaluate the efficacy (in terms of cardiovascular performance), safety, and adherence (in terms of dropout rate) to the exercise prescription after 6 and 12 months follow-up of a 3-month NW intervention compared with standard rehabilitation training (SR, 3 months) in obese/overweight diabetic patients with cardiovascular (CV) complications. The study will enroll in parallel a control group that can access only generic cardiological counseling with a prescription for unsupervised home exercise.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Nordic Walking (NW) — The experimental group will carry out NW sessions three times a week for 12 weeks, supervised by a NW instructor and under the control of a cardiologist. The duration of each NW session will initially be 90 minutes: 10 minutes of warm-up, 60 of NW, and 15 minutes of cool-down. The intensity of the course will be gradually increased each week, starting at 70 to 85% of the heart rate (HR) reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
  • Other: Standard Rehabilitation (SR) — The second group will follow a standard rehabilitation program with an initial cardiological prescription and supervised by physiotherapists, carried out 5 days a week with sessions lasting 40 minutes, including 5 minutes of warm-up up), 30 min of aerobic physical activity on a conveyor belt or cycle ergometer and 5 minutes of cooling down (cool down). The intensity of your aerobic activity will gradually increase each week, starting at 70 to 85% of HR reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
  • Other: Cardiological Counselling (CC) — The third group of participants will receive cardiological counselling with indications of unsupervised aerobic physical activity. The group will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.

Primary Outcomes

  • Six Minute Walking Test (6MWT) distance in meters (An average of 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 105 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Don Carlo Gnocchi ETS
Principal Investigators:
  • Anna Torri, MD (PRINCIPAL_INVESTIGATOR) - IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy
Contact Information
Study Contact:
Nuccia Morici, MD, Ph.D.
3206359064
nmorici@dongnocchi.it
Anna Torri, MD
3477408748
atorri@dongnocchi.it
IRCCS Fondazione Don Carlo Gnocchi
Eleonora Volpato, Psy.D, Ph.D.
3293782692
evolpato@dongnocchi.it
IRCCS Fondazione Don Carlo Gnocchi
Interventions
  • Other: Nordic Walking (NW) — The experimental group will carry out NW sessions three times a week for 12 weeks, supervised by a NW instructor and under the control of a cardiologist. The duration of each NW session will initially be 90 minutes: 10 minutes of warm-up, 60 of NW, and 15 minutes of cool-down. The intensity of the course will be gradually increased each week, starting at 70 to 85% of the heart rate (HR) reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
  • Other: Standard Rehabilitation (SR) — The second group will follow a standard rehabilitation program with an initial cardiological prescription and supervised by physiotherapists, carried out 5 days a week with sessions lasting 40 minutes, including 5 minutes of warm-up up), 30 min of aerobic physical activity on a conveyor belt or cycle ergometer and 5 minutes of cooling down (cool down). The intensity of your aerobic activity will gradually increase each week, starting at 70 to 85% of HR reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
  • Other: Cardiological Counselling (CC) — The third group of participants will receive cardiological counselling with indications of unsupervised aerobic physical activity. The group will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
Study Locations (1 sites)
IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148 Italy
Eligibility Criteria
Inclusion Criteria: \- overweight \[Body Mass Index (BMI) ≥ 27 kg/m2\] or obese (BMI ≥30 kg/m2) adult patients with diabetes mellitus and with a recent cardiovascular event and/or coronary revascularization in the previous three months Exclusion Criteria: * inability to walk independently and constantly; * acute joint or spine pathologies that make movement impossible; * the presence of dementia as approved by consultation of the patient's medical record and/or administration of the Montreal Cognitive Assessment (MOCA) test ≤ 15.5 (Nasreddine et al., 2005); * chemotherapy 6 months before surgery; * advanced renal failure; * acute cardiovascular event \< 3 months (unstable angina, AMI with FE \<40%, arrhythmias, valvular disease, intracerebral/subdural haemorrhage, uncontrolled AI); * home oxygen therapy and Non-Invasive Ventilation (NIV) \[excluding Continuous Positive Airway Pressure (CPAP)\].
Conditions Invasive Ductal Breast Carcinoma, Invasi...
Phase NA
Enrollment 26
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Palliative radiotherapy — Palliative radiotherapy (RT) will be performed using external beam ionizing radiation in accordance with standard practice

Primary Outcomes

  • Overall Response Rate (ORR) (12 weeks from baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-24
Completion: 2027-07-24
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 26 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Varian Medical Systems
Principal Investigators:
  • Atif Khan, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Atif Khan, MD
848-225-6334
khana7@mskcc.org
Christopher Barker, MD
212-639-8168
barkerc@mskcc.org
Atif Khan, MD
848-225-6334
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Interventions
  • Radiation: Palliative radiotherapy — Palliative radiotherapy (RT) will be performed using external beam ionizing radiation in accordance with standard practice
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Patients with biopsy confirmed advanced/metastatic solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of extracranial metastatic disease measuring at least 5 cm in a single axis. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines. * Age ≥ 18 years * ECOG Performance Status of 0 or 1. Exclusion Criteria: * Patients who are pregnant or breastfeeding * Prior radiation therapy to the candidate metastatic sites under consideration for treatment ("re-irradiation" is disallowed). * Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient. * Patients with a "currently active" metastatic second malignancy. * Patients on oral or parental corticosteroids. Physiological doses of steroids are permitted (eg for patients with adrenal insufficiency). If patients are on supraphysiological doses of steroids, these must be discontinued and held during the period of the study. * Concomitant anti-neoplastic treatment is not allowed during the days of radiation treatment delivery and should be completed or held for 3 days prior to commencement of protocol treatment and for 3 days following completion of radiotherapy, or with resolution of associated acute toxicities. * Unwilling or unable to participate in all required study evaluations and procedures. * Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).
Conditions Depression
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1. What are the outcomes of patients who screen positive for depressive symptoms and are prescribed either an Selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI). 2. What are the outcomes of patients who screen positive for depressive symptoms and choose not to pursue treatment with medication?

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Fluoxetine 20 MG — Fluoxetine 20 mg once daily
  • Drug: Duloxetine 30 MG — Duloxetine 30 mg once daily
  • Other: Observation — Referral to behavioral health and resources for addressing depressive symptoms

Primary Outcomes

  • Depressive Symptom Scores (Baseline)
  • Depressive Symptom Scores (Month 3)
  • Depressive Symptom Scores (Month 6)
  • Depressive Symptom Scores (Month 9)
  • Depressive Symptom Scores (Year 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-06-25
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Principal Investigators:
  • Meghan K Wally, PhD (PRINCIPAL_INVESTIGATOR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Erica Grochowski, MPH
704-403-4980
Erica.Grochowski@advocatehealth.org
Erica Grochowski, MPH
704-403-4980
Erica.Grochowski@atriumhealth.org
Wake Forest University Health Sciences
Interventions
  • Drug: Fluoxetine 20 MG — Fluoxetine 20 mg once daily
  • Drug: Duloxetine 30 MG — Duloxetine 30 mg once daily
  • Other: Observation — Referral to behavioral health and resources for addressing depressive symptoms
Study Locations (1 sites)
Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157 United States
Eligibility Criteria
Inclusion Criteria: * Patients presenting to an Orthopaedic trauma clinic for the first time following operative extremity fracture or any pelvis fracture * A score of greater than or equal to 5 on the Patient Health Questionnaire-9 (PHQ-9) at first post- operative visit * Age 18 or older * Speak English or Spanish Exclusion Criteria: * Currently taking medication to treat depression * Contraindication/allergy to one of the study medications * Bipolar disorder of psychotic disorder * Endorse suicidal ideation
Conditions Heart Failure, Type2diabetes, Insulin Re...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Diabetes can lead to heart failure independently, but the underlying causes remain incompletely understood. The main aim of this study is to identify differential regulation of mitochondrial substrate utilization and complex activity in heart failure and type 2 diabetes mellitus (T2DM). For this, we will conduct a prospective, observational study to examine myocardial mitochondrial oxidative function and related metabolic parameters, gene expression, histological markers, and inflammation in cardiac tissue from patients with heart failure or patients after heart transplantation. We will further assess cardiac function using cardiac magnetic resonance imaging with and without stress protocols and magnetic resonance spectroscopy. Glycemic control/T2DM will be characterized by oral glucose tolerance tests. The results of this project will help to better understand the cellular mechanisms of the development of diabetic cardiomyopathy and contribute to the development of early diagnostic, as well as therapeutic approaches for the prevention and treatment of diabetic cardiomyopathy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Substrate-specific JVO2 of ventricular myocardial mitochondrial oxidative capacity (at time of the endomyocardial biopsy procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-12-01
Completion: 2035-06
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Heinrich-Heine University, Duesseldorf
Principal Investigators:
  • Malte Kelm, Prof. (STUDY_CHAIR) - Clinic for Cardiology, Pneumology and Angiology at University Hospital Düsseldorf
  • Elric Zweck, MD (PRINCIPAL_INVESTIGATOR) - Clinic for Cardiology, Pneumology and Angiology at University Hospital Düsseldorf
Contact Information
Study Contact:
Elric Zweck, MD
+492118118800
elric.zweck@med.uni-duesseldorf.de
Amin Polzin, MD
+49211811800
amin.polzin@med.uni-duesseldorf.de
Lisa Dannenberg, MD
lisa.dannenberg@med.uni-duesseldorf.de
University-Hospital Düsseldorf Division of Cardiology, Pulmonary Disease and Vascular Medicine
Interventions
N/A
Study Locations (1 sites)
University-Hospital Düsseldorf Division of Cardiology, Pulmonary Disease and Vascular Medicine, Düsseldorf, 40225 Germany
Eligibility Criteria
Inclusion Criteria: * Age ≥ 20 and ≤ 85 years * Male and female patients with manifest heart failure (NYHA II-IV) and clinical indication for myocardial biopsy or after transplantation and clinical indication for myocardial biopsy with or without type II diabetes mellitus or terminal (NYHA IV) heart failure with or without type II diabetes mellitus. * Written informed consent Exclusion Criteria: * Acute infectious diseases within the last 2 weeks before the examination * Autoimmune diseases or acute immunocompromising diseases (leukocytes \< 5000/μl) * Pregnancy * Use of alcohol or drugs (addiction), psychiatric diseases * Suspected or manifest AIDS (HIV); hepatitis B or C. * Liver disease not attributed to the presence of nonalcoholic fatty liver hepatitis or congestive hepatopathy in heart failure * Malignant cancer * Lack of capacity to give informed consent or lack of consent to participate in the study * For MRI study with drug stress: contraindications to the use of regadenoson, specifically: a) Hypersensitivity to the active ingredient or any of the other ingredients mentioned. b) Second- or third-degree atrioventricular (AV) block or sinus node dysfunction, unless these patients have a functioning pacemaker. c) Unstable angina that has not been stabilized with medication. d) Severe hypotension. e) Decompensated stages of heart failure.
Conditions Depression, Epilepsy
Phase NA
Enrollment 58
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression is one of the most common disorders of mental health, affecting 7-8% of the population and causing tremendous disability to afflicted individuals and economic burden to society. In order to optimize existing treatments and develop improved ones, the investigators need a deeper understanding of the mechanistic basis of this complex disorder. Previous work in this area has made important progress but has two main limitations. (1) Most studies have used non-invasive and therefore imprecise measures of brain activity. (2) Black box modeling used to link neural activity to behavior remain difficult to interpret, and although sometimes successful in describing activity within certain contexts, may not generalize to new situations, provide mechanistic insight, or efficiently guide therapeutic interventions. To overcome these challenges, the investigators combine precise intracranial neural recordings in humans with a suite of new eXplainable Artificial Intelligence (XAI) approaches. The investigators have assembled a team of experimentalists and computational experts with combined experience sufficient for this task. Our unique dataset comprises two groups of subjects: the Epilepsy Cohort consists of patients with refractory epilepsy undergoing intracranial seizure monitoring, and the Depression Cohort consists of subjects in an NIH/BRAIN-funded research trial of deep brain stimulation for treatment-resistant depression (TRD). As a whole, this dataset provides precise, spatiotemporally resolved human intracranial recording and stimulation data across a wide dynamic range of depression severity. Our Aims apply a progressive approach to modeling and manipulating brain-behavior relationships. Aim 1 seeks to identify features of neural activity associated with mood states. Beginning with current state-of-the-art AI models and then uses a "ladder" approach to bridge to models of increasing expressiveness while imposing mechanistically explainable structure. Whereas Aim 1 focuses on self-reported mood level as the behavioral index of interest, Aim 2 uses an alternative approach of focusing on measurable neurobiological features inspired by the Research Domain Criteria (RDoC). These features, such as reward sensitivity, loss aversion, executive attention, etc. are extracted from behavioral task performance using a novel "inverse rational control" XAI approach. Relating these measures to neural activity patterns provides additional mechanistic and normative understanding of the neurobiology of depression. Aim 3 uses recurrent neural networks to model the consequences of richly varied patterns of multi-site intracranial stimulation on neural activity. Then employing an innovative "inception loop" XAI approach to derive stimulation strategies for open- and closed-loop control that can drive the neural system towards a desired, healthier state. If successful, this project would enhance our understanding of the pathophysiology of depression and improve…

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Factorial Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Device: Brain Stimulation — Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care, respectively, The depression cohort will also have deep brain stimulation (DBS) leads implanted as part of their trial. We will deliver stimulation via the DBS and sEEG electrodes. We will adhere to well known safety parameters.
  • Device: sEEG Stimulation — Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care. We will deliver stimulation via the sEEG electrodes. We will adhere to well known safety parameters.

Primary Outcomes

  • Daily Mood Assessment - CAT-DI (Epilepsy patients: 10 days; Depression: 2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-03
Completion: 2028-03
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baylor College of Medicine
Collaborators: University of Minnesota, University of Texas
Contact Information
Study Contact:
Sameer Sheth, MD, PhD
713-798-5060
sameer.sheth@bcm.edu
Victoria Pirtle
victoria.pirtle@bcm.edu
Victoria Pirtle
victoria.pirtle@bcm.edu
Baylor College of Medicine
Interventions
  • Device: Brain Stimulation — Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care, respectively, The depression cohort will also have deep brain stimulation (DBS) leads implanted as part of their trial. We will deliver stimulation via the DBS and sEEG electrodes. We will adhere to well known safety parameters.
  • Device: sEEG Stimulation — Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care. We will deliver stimulation via the sEEG electrodes. We will adhere to well known safety parameters.
Study Locations (1 sites)
Baylor College of Medicine, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Epilepsy cohort: adult patients scheduled to undergo intracranial seizure monitoring who provide informed consent * Depression cohort: patients enrolled in our DBS for depression trial
Conditions Major Depressive Disorder, Major Depress...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder(MDD) is a complex and heterogeneous mental disorder. Repeated transcranial magnetic stimulation (rTMS), as a non-invasive neuroregulatory technique, has shown a promising function in the treatment of depression. Theta-burst transcranial magnetic stimulation (TBS) model significantly shortened the duration of physical therapy treatment, and iTBS under the accelerated model (The latter is referred to as aiTBS)showed promising therapeutic effect. However, whether aiTBS has a better and faster curative effect in the first untreated or recurrent unmedicated MDD patients and the mechanism of its alleviation of depressive symptoms remains unclarified. This project intends to verify changes in CAMKII levels, CAMKII molecules and GABA receptors in brain-derived exosomes in normal controls and patients who received sham, aiTBS and high-frequency (10Hz) stimulation respectively. Neuroimaging and TMS-EEG were used to pinpoint the target of stimulation and to record the changes of brain waves before and after treatment in real time. To clarify the neurobiological mechanism of aiTBS rapidly improving depression, and to provide a new strong evidence for clinical transcranial magnetic stimulation for accurate treatment of MDD patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: sham stimulation — The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
  • Device: accelerated intermittent theta burst stimulation — Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT. Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
  • Device: high frequency stimulation — Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT. Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.

Primary Outcomes

  • Hamilton depression scale-24 (baseline)
  • Hamilton depression scale-24 (5days)
  • Hamilton depression scale-24 (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-09
Completion: 2027-03-15
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Zhejiang University
Contact Information
Study Contact:
Manli Huang, Dr
+86 13957162975
huangmanli@zju.edu.cn
the First Affiliated Hospital,Zhejiang University School of Medicine
Interventions
  • Device: sham stimulation — The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
  • Device: accelerated intermittent theta burst stimulation — Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT. Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
  • Device: high frequency stimulation — Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT. Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
Study Locations (1 sites)
the First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang China
Eligibility Criteria
Inclusion Criteria: * Sign a written informed consent to participate in the trial and receive treatment; * Major depressive disorder diagnosis; * Hamilton depression scale (HAMD - 24) 24 total score 20 points or more; * First episode or recurrence of depression patients, not taking psychiatric drugs; * The han nationality, right-handed; * Junior high school or above; Exclusion Criteria: * Other organic mental disorders and mental retardation and other severe mental disorders; * Infection, trauma, and autoimmune diseases or other possible interference test evaluation of disease; * Alcohol and drug dependence or is being treated for a hormone drugs patients; * Craniocerebral injury; * Seizure or a family history of epilepsy; * Pregnancy and lactation women; * All landowners had a metal and MRI contraindications or MRI examination revealed abnormal brain structure.

Seroma of the Mammary Gland

NCT05899387
Recruiting
Conditions Seroma, Breast Cancer, Mastectomy, Breas...
Phase NA
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study is designed as international, prospective, minimal interventional study in cooperation with EUBREAST e.V. (European Breast Cancer Research Association of Surgical Trialists). Furthermore, it is planned to initiate a registry for postoperative breast seromas.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Procedure: Swap collection — Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards. In addition, taking swabs intraoperatively according to protocol from skin and surgical site.
  • Procedure: Seroma punction — Puncturing of a seroma in case of occurence and clinical need
  • Procedure: Blood sampling — Blood sampling at defined time points according to protocol
  • Diagnostic Test: Sonographic correlation Seroma — If a seroma occurs, a sonographic correlation is performed to determine the exact size of the seroma

Primary Outcomes

  • Identification of a patient population at increased risk for developing seroma. (Follow-up for each participant: 6 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Augsburg
Principal Investigators:
  • Thorsten Kühn, Prof. (STUDY_CHAIR) - Eubreast Network, Baumreute 37 D-73730 Esslingen, Germany
  • Nina Ditsch, Prof. (PRINCIPAL_INVESTIGATOR) - University Hospital Augsburg, Stenglinstr. 2, D-86156 Augsburg, Germany
Contact Information
Study Contact:
Nina Ditsch, Prof.
+49 (0)821 400 165809
nina.ditsch@uk-augsburg.de
Melitta Köpke, Dr. med.
+49 (0)821 400 165862
melitta.koepke@uk-augsburg.de
Nina Ditsch, Prof.
nina.ditsch@uk-agsburg.de
University Hospital Augsburg, Department of Gynecology and Obstetrics
Interventions
  • Procedure: Swap collection — Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards. In addition, taking swabs intraoperatively according to protocol from skin and surgical site.
  • Procedure: Seroma punction — Puncturing of a seroma in case of occurence and clinical need
  • Procedure: Blood sampling — Blood sampling at defined time points according to protocol
  • Diagnostic Test: Sonographic correlation Seroma — If a seroma occurs, a sonographic correlation is performed to determine the exact size of the seroma
Study Locations (1 sites)
University Hospital Augsburg, Department of Gynecology and Obstetrics, Augsburg, Bavaria 86156 Germany
Eligibility Criteria
Inclusion criteria study group and control group 1: * Written informed consent * Age ≥ 18 years * all stages of DCIS or primary breast cancer (T1-T4, N0 or N+, M0) including all histopathological subtypes (ER/PR positive, ER positive/PR negative, Her-2/neu positive and triple negative) * Surgical procedure planned including ablatio or subcutaneous mastectomy with implant or expander insertion Inclusion criteria control group 2 and 3: * Written informed consent * Age ≥ 18 years * Surgical procedure planned with implant or expander insertion with or without subcutaneous mastectomy Exclusion criteria: * Age \<18 years * Male sex * Breast cancer patients planned for breast conserving therapy * Recurrent breast cancer disease * History of breast surgery * Diagnosis of LCIS only * Pregnancy at time of diagnosis * Patients with a known immunodeficiency